SEC Form 4 · accession 0000899866-15-000071
ALEXION PHARMACEUTICALS, INC. · ALXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dominique Monnet
Officer — SVP, Chief Marketing Officer
Period of report
Feb 27, 2015
Accepted (ET)
Mar 3, 2015 · 9:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000899866
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $.0001 per shareF1 | Feb 27, 2015 | A | 3,830 | $0.00 | A | 9,043 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2 | $180.37 | Feb 27, 2015 | A | 18,300 | A | Feb 27, 2016 | Feb 27, 2025 | Common Stock, par value $.0001 per share | 18,300 | 18,300 | D |
Explanation of responses
- F1Award of Restricted Stock Units under the 2004 Incentive Plan. 25% vests on each anniversary of the grant date.
- F225% vests on the first anniversary of the grant date and 1/16 every three months thereafter.